FDA Safety Data-mining In Literature To Start With Fluoroquinolones, Lipid Drugs
This article was originally published in The Pink Sheet Daily
The agency is seeking a contractor to develop a tool to examine the National Library of Medicine’s MEDLINE database of biomedical articles, with pilot studies that seemed aimed at quantification of already-know risks.
You may also be interested in...
Risk of peripheral neuropathy is already in labeling and FDA doesn’t want to require a black box, illustrating the agency’s ongoing challenge to fully communicate risks without unduly limiting access or use.
FDA's risk evaluation and mitigation strategy for fluoroquinolone antibiotics requires manufacturers to survey patients and prescribers to make sure they understand the risks of tendon injury associated with the products
AstraZeneca's Crestor falls in the middle of the statin pack in terms of class-related adverse events in actual practice, according to preliminary results of a claims database analysis by the National Lipid Association